10 results about "Lipoma" patented technology

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal / Skeletal Anomalies and / or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal / Skeletal Anomalies and / or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal / Skeletal Anomalies and / or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

Provided herein are compositions and methods for the treatment of Multiple Symmetric Lipomatosis (MSL) and related diseases and conditions. In particular, the present disclosure provides methods for the use of leptin receptor agonists (e.g., synthetic (e.g., recombinant) leptin, e.g., Metreleptin), in the treatment of Multiple Symmetric Lipomatosis (MSL) and related diseases and conditions.

Doxycycline injections improve the appearance of cosmetically significant lower eyelid festoons and malar edema, as well as of the jowls. The doxycycline is also useful for reducing edema of turbinates, the nasal concha or conchae shell-shaped networks of bones, vessels, and tissue within the nasal passageways that are responsible for warming, humidifying, and filtering the air as it is inhaled. The doxycline, in a concentration preferably of greater than 10 to 20 mg / ml, preferably in combination with a local anesthetic and optionally with a vasoconstrictor such as epinephrine and a pH buffering agent, is injected into the subcuticular space at the site of swelling. The high viscosity limits the spread of the doxycycline to the area to be treated. The resulting sclerosis prevents fluid accumulation. The doxycline also decreases swelling due to fat, by causing a decrease in lipomas.

The invention relates to the use of a pharmaceutical medication comprising an aromatase inhibitor, preferably a steroidal aromatase inactivator and an antioxidant as effective ingredients for the treatment of sex hormone-dependent diseases. Furthermore, the invention relates to a composition comprising an aromatase inhibitor / —inactivator and α-lipoic acid and / or extract of green tea containing polyphenols. The combination of an aromatase inhibitor and—inactivator and α-lipoic acid and / or extract of green tea containing polyphenols is particularly suitable for the treatment of sex hormone-dependent diseases as well as for the treatment of benign tumors such as e.g. lipomatoses as occurring in Madelung's disease.

Provided herein are compositions and methods using a therapeutic agent targeting mTORCI and a therapeutic agent targeting MDK for treating a Tuberous Sclerosis Complex (TSC)-associated disease, e.g., Angiomyolipoma (AML) and lymphangioleiomyomatosis (LAM), or for treating sporadic LAM / AML. Also provided are methods of identifying subjects for treatment, e.g., with checkpoint inhibitors.

This invention relates to the field of computer-aided diagnostic technology, and provides a method for constructing an intelligent pathological auxiliary diagnostic model for lipomas based on weakly supervised learning. The method includes acquiring several whole-slice images of lipomas; preprocessing the whole-slice images; constructing a structured square image patch dataset suitable for weakly supervised learning; classifying and storing the images according to their dataset and pathological label categories in a structured text index file; constructing a lightweight ViT model as the core network architecture, serializing and embedding the square image patches, learning features through a multi-layer self-attention mechanism, and connecting them to a global pooling classification head to form a weakly supervised diagnostic model that relies on image-level labels for end-to-end training; and applying weakly supervised training strategies and optimizations to the weakly supervised diagnostic model to achieve an interpretable intelligent diagnostic system for lipomas. This invention constructs an end-to-end solution suitable for weakly supervised learning of pathological images.

The invention provides application of AS-605240 in treatment of renal vascular smooth muscle lipoma related to nodular sclerosis, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, the AS-605240 can be used for directly inhibiting the cell growth of the renal vascular smooth muscle lipoma related to the nodular sclerosis, and the AS-605240 can be used for preparing a medicine for resisting the renal vascular smooth muscle lipoma related to the nodular sclerosis, so that a new potential medicine is provided for treating the renal vascular smooth muscle lipoma related to the nodular sclerosis. The invention proves that AS-605240 can promote apoptosis of renal vascular smooth muscle lipoma cells related to the nodular sclerosis through a non-mTOR target point PI3K / AKT, so that the AS-605240 can treat the renal vascular smooth muscle lipoma related to the nodular sclerosis, and has good treatment and improvement effects on the renal vascular smooth muscle lipoma related to the nodular sclerosis.

The present invention belongs to the field of biomedicine technology and specifically relates to the use of artemisinin compounds in the preparation of drugs for treating tuberous sclerosis complex-associated renal angiomyolipoma. The artemisinin compounds can inhibit the growth of tuberous sclerosis complex-associated renal angiomyolipoma cells and have therapeutic efficacy in treating tuberous sclerosis complex-associated renal angiomyolipoma. Furthermore, artemisinin compounds are relatively abundant in source and relatively low in cost. Artemisinin compounds can be used to prepare drugs for treating tuberous sclerosis complex-associated renal angiomyolipoma, providing a new potential drug for the treatment of tuberous sclerosis complex-associated renal angiomyolipoma.